Kintor Pharmaceutical Future Growth

Future criteria checks 2/6

Kintor Pharmaceutical is forecast to grow earnings and revenue by 25.8% and 160% per annum respectively while EPS is expected to grow by 27.8% per annum.

Key information

25.8%

Earnings growth rate

27.8%

EPS growth rate

Biotechs earnings growth	39.1%
Revenue growth rate	160.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	16 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SEHK:9939 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	388	-615	-597	-1,016	1
12/31/2024	103	-800	-824	-1,145	1
6/30/2024	N/A	-920	-287	-284	N/A
3/31/2024	N/A	-991	-339	-336	N/A
12/31/2023	N/A	-1,061	-390	-388	N/A
9/30/2023	N/A	-854	-437	-427	N/A
6/30/2023	N/A	-648	-484	-467	N/A
3/31/2023	N/A	-801	-736	-714	N/A
12/31/2022	N/A	-954	-989	-961	N/A
9/30/2022	17	-995	-1,192	-1,144	N/A
6/30/2022	34	-1,035	-1,396	-1,328	N/A
3/31/2022	34	-938	-1,276	-1,190	N/A
12/31/2021	34	-842	-1,157	-1,051	N/A
9/30/2021	17	-740	-960	-851	N/A
6/30/2021	N/A	-639	-763	-650	N/A
3/31/2021	N/A	-573	-620	-516	N/A
12/31/2020	N/A	-508	-477	-381	N/A
9/30/2020	N/A	-419	-430	-341	N/A
6/30/2020	N/A	-330	-382	-301	N/A
3/31/2020	N/A	-281	-342	-264	N/A
12/31/2019	N/A	-233	-302	-228	N/A
12/31/2018	1	-108	-134	-115	N/A
12/31/2017	0	-46	N/A	-45	N/A
9/30/2017	0	-41	N/A	-36	N/A
6/30/2017	0	-35	N/A	-27	N/A
3/31/2017	1	-45	N/A	-21	N/A
12/31/2016	1	-54	N/A	-15	N/A
12/31/2015	N/A	-11	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9939 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 9939 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 9939 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 9939's revenue (160% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 9939's revenue (160% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 9939's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 06:26
End of Day Share Price	2024/12/31 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kintor Pharmaceutical Limited is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peng Zou	China International Capital Corporation Limited
Bing Zhao	China Renaissance Securities
Blanco Zhou	China Renaissance Securities

Kintor Pharmaceutical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast to breakeven in 2023

Consensus revenue estimates fall by 98%

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Consensus forecasts updated

Recent updates

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase III Stage

Founder recently bought HK$259k worth of stock

New major risk - Revenue and earnings growth

Founder recently bought HK$107k worth of stock

Kintor Pharmaceutical Limited Receives Review Approval of Incorporation for KT-939

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Pivotal Clinical Trial of Kx-826 Tincture 1.0% for the Treatment of Men Adult Androgenetic Alopecia in China

Founder recently bought HK$248k worth of stock

Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?

Founder recently bought HK$249k worth of stock

Founder recently bought HK$424k worth of stock

Kintor Pharmaceutical Limited to Report First Half, 2024 Results on Aug 26, 2024

Founder recently bought HK$294k worth of stock

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of GT20029 Gel for Treatment of Ance in China

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 20, 2024

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint

Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New major risk - Share price stability

Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA

Founder recently bought HK$774k worth of stock

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

New minor risk - Share price stability

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

New major risk - Financial position

Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Insider recently sold HK$2.6m worth of stock

Insider recently sold HK$42m worth of stock

New major risk - Revenue and earnings growth

Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China

Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023

Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 15, 2023

Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China

Insider recently sold HK$12m worth of stock

Forecast to breakeven in 2023

Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound

Kintor Pharmaceutical Limited has completed a Follow-on Equity Offering in the amount of HKD 517.6 million.

Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China

Kintor Pharmaceutical Limited Announces Publication of Phase Ib Data from Pruxelutamide for Ar+ Mbc in Ejc

Consensus revenue estimates fall by 98%

Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022

Kintor Pharmaceutical Limited Completes Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the Us

Key Executive recently sold HK$5.7m worth of stock

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 30, 2022

Insider recently sold HK$60m worth of stock

Kintor Pharmaceutical Limited Announces Board Changes

Kintor Pharmaceutical Limited Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

Forecast breakeven date pushed back to 2023

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Top-Line Results of the Phase III MRCT of Proxalutamide in Outpatients with Mild to Moderate Covid-19

Forecast breakeven date pushed back to 2023

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Aga in Female Patients

Kintor Pharma Limited Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

Kintor Pharmaceutical Limited Announces Executive Changes

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

Kintor Pharmaceutical Limited Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne

Kintor Pharma Announces Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

Kintor Pharmaceutical Limited Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China

Kintor Pharmaceutical Limited Provides Update Interim Analysis for Phase III Study of Proxalutamide for Patients with Mild to Moderate Covid-19 Symptoms

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Deputy GM & Joint Company Secretary Jie Chen has left the company

Non-Executive Director Wei Zhang has left the company

Kintor Pharmaceutical Limited Receives IND Clearance by NMPA for KX-826